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Abstract  The  Diabetes  and  Cardiovascular  Disease  study  group  of  the  Société  francophone
du diabète  (SFD,  French  Society  of  Diabetes)  in  collaboration  with  the  Société  franc¸aise  de
cardiologie  (SFC,  French  Society  of  Cardiology)  have  devised  a  consensus  statement  on  the
care of  the  hyperglycaemic/diabetic  patient  during  and  in  the  immediate  follow-up  of  acute
coronary syndrome  (ACS);  in  particular,  it  includes  the  different  phases  of  ACS  [the  intensive
care unit  (ICU)  period,  the  post-ICU  period  and  the  short-term  follow-up  period  after  discharge,
including cardiac  rehabilitation]  and  also  embraces  all  of  the  various  diagnostic  and  therapeutic
issues with  a  view  to  optimizing  the  collaboration  between  cardiologists  and  diabetologists.  As
regards diagnosis,  subjects  with  HbA1c greater  or  equal  to  6.5%  on  admission  may  be  considered
diabetic while,  in  those  with  no  known  diabetes  and  HbA1c less  than  6.5%,  it  is  recommended
that an  OGTT  be  performed  7  to  28  days  after  ACS.  During  hospitalization  in  the  ICU,  continuous
insulin treatment  should  be  initiated  in  all  patients  when  admission  blood  glucose  levels  are
greater or  equal  to  180  mg/dL  (10.0  mmol/L)  and,  in  those  with  previously  known  diabetes,  when
preprandial  glucose  levels  are  greater  or  equal  to  140  mg/dL  (7.77  mmol/L)  during  follow-up.
The recommended  blood  glucose  target  is  140—180  mg/dL  (7.7—10  mmol/L)  for  most  patients.
Following the  ICU  period,  insulin  treatment  is  not  mandatory  for  every  patient,  and  other
antidiabetic  treatments  may  be  considered,  with  the  choice  of  optimal  treatment  depending
on the  metabolic  proﬁle  of  the  patient.  Patients  should  be  referred  to  a  diabetologist  before
discharge  from  hospital  in  cases  of  unknown  diabetes  diagnosed  during  ACS  hospitalization,  of
HbA1c greater  or  equal  to  8%  at  the  time  of  admission,  or  newly  introduced  insulin  therapy
or severe/repeated  hypoglycaemia.  Referral  to  a  diabetologist  after  hospital  discharge  is  rec-
ommended  if  diabetes  is  diagnosed  by  the  OGTT,  or  during  cardiac  rehabilitation  in  cases  of
uncontrolled  diabetes  (HbA1c ≥  8%)  or  severe/repeated  hypoglycaemia.
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Résumé  Le  groupe  d’étude  Cœur  et  Diabète  de  la  Société  francophone  du  diabète  (SFD),
en collaboration  avec  la  Société  franc¸aise  de  cardiologie  (SFC),  a  rédigé  un  consensus  sur  la
« prise  en  charge  du  patient  diabétique/hyperglycémique  au  cours  et  au  décours  immédiat  d’un
syndrome  coronaire  aigu  (SCA)  » en  intégrant  les  différentes  périodes  du  SCA  (soins  intensifs,
hospitalisation  post-soins  intensifs  et  le  suivi  immédiat  incluant  la  réadaptation  cardiaque),
en considérant  aussi  bien  les  problèmes  diagnostiques  que  thérapeutiques  et  dans  le  souhait
d’optimiser  la  collaboration  entre  cardiologues  et  diabétologues.  En  ce  qui  concerne  le  diagnos-
tic, les  patients  qui  ont  une  HbA1c lors  de  l’admission  supérieure  ou  égale  à  6,5  %  peuvent  être
considérés  comme  diabétiques.  Chez  les  patients  non  diabétiques  dont  l’HbA1c est  inférieure
à 6,5  %,  il  est  recommandé  de  pratiquer  un  test  de  charge  en  glucose  sept  à  28  jours  après
le SCA.  Au  cours  de  l’hospitalisation  en  soins  intensifs,  un  traitement  par  insuline  devra  être
initié, chez  tous  les  patients,  en  cas  de  glycémie  à  l’admission  supérieure  ou  égale  à  1,80  g/L
(10,0 mmol/L)  et,  chez  les  patients  diabétiques  connus  avant  le  SCA,  en  cas  de  glycémie  pré-
prandiale supérieure  ou  égale  à  1,40  g/L  (7,77  mmol/L).  L’objectif  glycémique  pour  la  majorité
des patients  doit  se  situer  entre  1,40  et  1,80  g/L  (7,7—10  mmol/L).  Après  l’hospitalisation  en
soins intensifs,  le  traitement  insulinique  n’est  pas  obligatoire  chez  tous  les  patients  et  il  sera
possible  d’utiliser  d’autres  traitements  antidiabétiques  dont  le  choix  sera  dicté  par  le  proﬁl
métabolique  du  patient  diabétique.  Le  patient  devra  être  adressé  à  un  diabétologue,  avant
sa sortie  de  l’hôpital,  dans  les  situations  suivantes  :  diabète  diagnostiqué  lors  du  SCA,  HbA1c à
l’admission  supérieure  ou  égale  à  8  %,  instauration  d’un  traitement  par  insuline  et/ou  hypogly-
cémies répétées  ou  sévères.  Au  décours  de  l’hospitalisation,  une  consultation  diabétologique
sera demandée  en  cas  de  diabète  diagnostiqué  lors  du  test  de  charge  en  glucose  et,  au  cours  de
la réadaptation  cardiaque,  en  cas  de  diabète  mal  contrôlé  (HbA1c ≥  8  %)  et/ou  d’hypoglycémies
répétées  ou  sévères.
beti
m
d
e
(
t
o
o
i
w
c
c
f
i
t
c
t
s
s
a
level  B  =  scientiﬁc  hypothesis  (based  on  low-quality  ran-
domized  comparative  trials,  well-designed  non-randomizedConsensus  statement  on  the  care  of  the  hyperglycaemic/dia
1. Introduction
Type  2  diabetes  is  a  major  risk  factor  of  cardiovascular  mor-
bidity  and  mortality  [1,2]. An  increased  cardiovascular  risk
is  already  present  in  those  with  mildly  elevated  levels  of
blood  glucose  that  are  still  below  the  threshold  for  diabetes
[3—5],  while  the  prevalence  of  diabetes  or  abnormal  glucose
metabolism  is  very  high  in  patients  presenting  with  acute
coronary  syndrome  (ACS).  Indeed,  among  patients  hospital-
ized  for  ACS,  30—40%  have  diabetes,  25—36%  show  impaired
fasting  glucose  (IFG)  or  impaired  glucose  tolerance  (IGT)  and
only  30—40%  have  normal  glucose  tolerance  [6—9]. In  addi-
tion,  the  prognosis  after  ACS  is  impaired  in  diabetic  patients
[9].  Thus,  diabetes  care  during  and  in  the  immediate  follow-
up  of  ACS  is  an  important  issue.  So  far,  recommendations
for  diabetes  treatment  during  ACS  are  limited,  with  no  spe-
ciﬁc  guidelines  for  glucose  management  in  ACS  patients,
and  no  consensus  on  the  use  of  non-insulin  treatments  dur-
ing  and  in  the  immediate  follow-up  of  ACS.  Furthermore,
cardiologists  have  no  clear  recommendations  as  to  when
to  refer  a  patient  to  a  diabetologist  during  and  following
ACS.  Moreover,  in  patients  presenting  with  ACS  and  hyper-
glycaemia,  but  with  no  previously  known  diabetes,  there  is
a  need  for  a  clear  diagnostic  pathway  for  the  diagnosis  and
Fig. 1. Summary of the consensus statement on care of the hyperglyc
an ACS.
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anagement  of  abnormal  glucose  metabolism  (IFG/IGT)  and
iabetes.
For  these  reasons,  the  Diabetes  and  Cardiovascular  Dis-
ase  study  group  of  the  Société  Francophone  du  Diabète
SFD,  French  Society  of  Diabetes)  in  collaboration  with
he  Société  Franc¸aise  de  Cardiologie  (SFC,  French  Society
f  Cardiology)  have  put  together  a  consensus  statement
n  the  care  of  the  hyperglycaemic/diabetic  patient  dur-
ng  and  in  the  immediate  follow-up  of  ACS.  The  objective
as  to  devise  a  consensus  statement  to  cover  the  hypergly-
aemic/diabetic  patient  during  each  phase  of  ACS  [intensive
are  unit  (ICU)  period,  post-ICU  period  and  short-term
ollow-up  period  after  discharge,  including  cardiac  rehabil-
tation]  while  embracing  all  of  the  various  diagnostic  and
herapeutic  issues  to  optimize  the  collaboration  between
ardiologists  and  diabetologists  (Fig.  1).  The  consensus  uses
he  recommendation  grades  of  the  French  Haute  Autorité  de
anté  (HAS,  National  Health  Authority):  Level  A  =  established
cientiﬁc  proof  (based  on  high-quality  randomized  compar-
tive  trials  or  meta-analysis  of  randomized  control  trials);aemic/diabetic patient during and in the immediate follow-up of
omparative  studies  or  cohort  studies);  and  level  C  =  low
evel  of  proof  (based  on  case—control  studies)  [10].
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. Screening for glucose metabolism
isorders in patients with ACS
.1. Stress hyperglycaemia
pidemiological  data  show  that  the  prevalence  of  known
iabetes  in  patients  referred  for  ACS  is  greater  or  equal  to
0%.  Stress  can  also  facilitate  the  development  of  abnormal
lucose  metabolism.  Therefore,  stress  hyperglycaemia  is
ommonly  found  in  patients  with  ACS,  and  is  a  powerful  pre-
ictor  of  in-hospital  survival  and  in-hospital  complications
n  patients  with  and  without  established  diabetes  [11,12].
t  has  also  been  suggested  that  tight  control  of  glycaemia
uring  the  acute  phase  might  improve  survival,  thereby
ustifying  the  routine  measurement  of  glucose  levels  on
dmission.  However,  admission  levels  of  glucose  are  not  a
ecognized  diagnostic  criterion  of  intermediate  hypergly-
aemia  or  diabetes,  and  do  not  predict  the  classiﬁcation
f  glucose  tolerance  after  ACS  [13—15]. Admission  glucose
evels  should  therefore  not  be  used  to  classify  glucose  tol-
rance,  but  rather  to  initiate  early  insulin  treatment.
.2. Deﬁnition and classiﬁcation of
ntermediate hyperglycaemia and diabetes
he  criteria  currently  used  in  France  [14]  are  those  estab-
ished  by  the  World  Health  Organization  (WHO)  based  on
he  level  of  fasting  plasma  glucose  (FPG)  and/or  glucose
evel  2  h  (2hPG)  after  an  oral  glucose  tolerance  test  (OGTT)
erformed  in  the  morning  after  a  12-h  fast  (with  a  75-g
lucose  load)  [13]. Diabetes  is  deﬁned  as  FPG  greater  or
qual  to  7.0  mmol/L  (126  mg/dL)  or  2hPG  greater  or  equal
o  11.1  mmol/L  (200  mg/dL).  IFG  is  deﬁned  as  FPG  greater  or
qual  to  6.1  mmol/L  (110  mg/dL)  and  less  than  7.0  mmol/L,
nd  IGT  is  deﬁned  as  a  2hPG  greater  or  equal  to  7.8  mmol/L
140  mg/dL)  and  less  than  11.1  mmol/L  [13]. The  American
iabetes  Association  (ADA)  has  recommended  decreasing
he  FPG  threshold  from  6.1  to  5.6  mmol/L  (100  mg/dL)  to
eﬁne  IFG,  thereby  replacing  the  OGTT  with  the  new  FPG
riterion  [16]. The  current  French  diagnostic  criteria  that
eﬁne  prediabetic  states  (IFG,  IGT)  and  diabetes  are  sum-
arized  below.
A recent  proposal  has  been  to  use  the  HbA1c as  a  diag-
ostic  criterion  for  diabetes  (HbA1c ≥  6.5%)  and  to  identify
ubjects  at  risk  of  future  diabetes,  using  a  threshold  of
reater  or  equal  to  6.0%  [17], lowered  to  greater  or  equal
o  5.7%  by  the  ADA  [16]. At  present,  the  use  of  the  HbA1c
s  a  diagnostic  criterion  for  intermediate  hyperglycaemia  or
iabetes  is  not  recommended  in  France.
.3. Screening for undiagnosed glucose
etabolism disorders
.3.1.  Which  diagnostic  test?
uropean  epidemiological  studies  show  that  the  prevalence
f  abnormal  glucose  metabolism  at  the  time  of  hospital
ischarge  [6],  and  at  2  [18], 3  [6]  and  12  months  there-
fter  [19], is  extremely  high  not  only  in  ACS  patients  with
nown  diabetes,  but  also  in  those  with  no  known  diabetes;
ndeed,  about  a  third  of  these  patients  has  diabetes  and
nother  third  has  intermediate  hyperglycaemia.  Also,  these
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revalences  have  been  reported  to  be  almost  twice  as  high
n  patients  with  ACS  as  in  their  matched  controls  [20]. How-
ver,  the  OGTT  is  necessary  for  the  appropriate  classiﬁcation
f  glucose  tolerance  in  patients  with  ACS  [5,21],  as  FPG  mea-
urement  alone  leads  to  the  underdiagnosis  of  dysglycaemic
tates  in  two-thirds  of  ACS  patients  [6,15,20].  This  is  also
rue  when  5.6  rather  than  6.1  mmol/L  is  used  as  the  FPG
hreshold  [22]. In  fact,  a  European  expert  committee  has
ecently  recommended  the  OGTT  for  all  patients  following
CS  [23].
In addition,  there  are  few  data  on  the  use  of  HbA1c as
 diagnostic  criterion  for  diabetes  or  intermediate  hyper-
lycaemia  after  ACS.  In  theory,  the  HbA1c is  of  interest  as
t  reﬂects  exposure  to  hyperglycaemia  during  the  previous
—3  months  and,  therefore,  is  not  inﬂuenced  by  the  stress
aused  by  ACS.  However,  studies  of  series  of  patients  with-
ut  acute  disease  show  that  strategies  using  either  OGTT  or
bA1c do  not  diagnose  the  same  patients:  there  is  increasing
vidence  of  discrepancies  between  the  two  screening  meth-
ds  for  the  classiﬁcation  for  dysglycaemia  [24—26]. It  has
een  reported  that  admission  HbA1c levels  correlate  with
he  presence  of  diabetes  after  ACS  [6]  and  with  an  abnor-
al  OGTT  3  months  after  ACS,  with  an  adjusted  odds  ratio
OR)  of  3.8  (1.8—7.8)  for  HbA1c levels  greater  than  5.7%
27]. However,  admission  HbA1c values  in  patients  with  or
ithout  diabetes  3  months  thereafter  largely  overlap  [6,27].
onetheless,  following  ACS,  HbA1c levels  greater  or  equal  to
.5%  have  been  shown  to  have  a  positive  predictive  value  of
00%  for  a  2hPG  value  greater  or  equal  to  11.1  mmol/L  and
ould,  therefore,  be  used  instead  of  the  OGTT  to  diagnose
iabetes  after  ACS  [15].
.3.2.  When  to  test?
he  admission  glucose  level  and  an  OGTT  performed  early
fter  myocardial  infarction  (MI)  do  not  provide  reliable  infor-
ation  on  the  long-term  glucometabolic  state  [15,27].  When
GTT  results  at  the  time  of  hospital  discharge  in  patients
ith  ACS  were  compared  with  those  3  months  later  [28],
mong  the  patients  with  a  normal  OGTT,  48%  had  IGT  and  4%
ad  diabetes  after  3  months.  Of  those  with  diabetes  accord-
ng  to  the  OGTT  at  discharge,  53%  still  had  diabetes,  32%
ad  IGT  and  15%  had  a  normal  OGTT  3  months  thereafter.
he  results  of  OGTTs  performed  in  ACS  patients  at  hospital
ischarge  also  provide  reliable  information  on  the  glu-
ometabolic  state  at  12  months.  For  example,  of  42  patients
ith  diabetes  at  discharge,  the  OGTT  was  still  abnormal  in
lmost  all  cases  12  months  after  ACS:  12  patients  had  IGT
nd  27  still  had  diabetes  [19].
Should  the  OGTT  be  reassessed  later  after  ACS,  when
atients  are  in  a  stable  condition?  Wallander  et  al.  [19]
eported  that  a  repeat  OGTT  at  12  months  could  further
dentify  42%  of  subjects  with  abnormalities.
.3.3.  Who  to  screen?
s  the  usual  clinical  and  biological  factors  associated  with
bnormal  glucose  metabolism  overlap  considerably,  they  are
ot  clinically  relevant  as  a  screening  strategy  [6,22,27,28].
ndeed,  a  model  built  from  FPG,  high-density  lipoprotein
HDL)  cholesterol,  age  and  log-HbA1c to  classify  patients  into
ormal  glucose  tolerance,  IGT  and  diabetes  misclassiﬁed  44%
f  the  patients,  of  whom  18%  were  overdiagnosed  and  26%
Consensus  statement  on  the  care  of  the  hyperglycaemic/diabetic  patient  243
Table  1  Criteria  for  the  diagnosis  of  disorders  of  glucose  metabolism.
Fasting  plasma  glucose  in  mg/dL  (mmol/L)  2  h  after  oral  glucose  load  (75  g)  in  mg/dL  (mmol/L)
<  140  (7.8) 140—199  (7.8—11.0) ≥  200  (11.1)
<  110  (6.1) Normal  IGT  Diabetes
110—125  (6.1—6.9) IFG IFG  and  IGT Diabetes
≥  126  (7.0) Diabetes Diabetes Diabetes
IGT: impaired glucose tolerance; IFG: impaired fasting glucose; NB: the OGTT should be performed 7 to 28 days after ACS in stable
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were  underdiagnosed  [22]. Furthermore,  a  low  HbA1c does
not  predict  a  normal  OGTT  [15].
CONSENSUS  STATEMENT  (SCREENING  FOR  GLUCOSE
METABOLISM  DISORDERS)
1.  Admission  glucose  (Level  A)  as  fasting  plasma
glucose  (Level  A)  and  HbA1c (professional
agreement)  on  the  ﬁrst  day  after  ACS  should
be  measured  in  all  patients.
2.  Admission  glucose  diagnoses  stress  hyperglycaemia
and  leads  to  the  initiation  of  early  insulin  treatment
if  admission  glucose  is  greater  or  equal  to  180  mg/dL
(10.0  mmol/L;  Level  A).  However,  the  admission
glucose  level  cannot  predict  glucose  metabolism
disorders  in  stable  conditions  after  ACS  (Level  B).
3.  Fasting  plasma  glucose  should  be  used  to  manage
treatment  (Level  A).
4. Subjects  with  HbA1c greater  or  equal  to  6.5%  may
be  considered  diabetic  (professional  agreement).
5. In  patients  with  no  known  diabetes  and  HbA1c less
than  6.5%,  glucose  metabolism  disorders  after  ACS
should  be  assessed  using  the  OGTT  (Level  A),  as
measuring  only  FPG  leads  to  the  underdiagnosis  of
dysglycaemic  states  in  two-thirds  of  patients  (Level
A).  The  OGTT  should  be  performed  7  to  28  days
after  ACS  in  stable  conditions  (Level  B),  often  after
discharge  as  the  mean  duration  of  hospitalization
after  ACS  is  less  than  7  days.  The  diagnostic  criteria
are  similar  as  those  used  in  subjects  with  no
cardiovascular  history  (Table  1).
3. Diabetes care in cardiology intensive
care units
Poor  glycaemic  control  in  diabetic  patients  and  stress  hyper-
glycaemia  in  non-diabetic  subjects  are  both  associated  with
poorer  outcomes  after  acute  MI  [9].  However,  it  is  not  yet
clear  whether  strict  glycaemic  control  during  acute  MI  hos-
pitalizations  improves  outcomes.
3.1. Does intensive antidiabetic treatment in
a  cardiology ICU provide any beneﬁt?
Some  studies  have  shown  that  intensive  insulin  treatment
is  beneﬁcial.  The  Diabetes  Mellitus  Insulin—Glucose  Infusion
i
1
cn Acute  Myocardial  Infarction  (DIGAMI)  trial,  involving  620
iabetic  patients  with  acute  MI  and  glycaemia  greater  than
1  mmol/L  (198  mg/dL),  showed  that  an  insulin—glucose
nfusion  for  24  h,  followed  by  subcutaneous  insulin  four  times
aily  for  greater  or  equal  to  3  months,  compared  with  stan-
ard  treatment  (insulin  therapy  only  if  clinically  indicated)
nduced  not  only  a  signiﬁcant  reduction  in  HbA1c,  but  also  a
igniﬁcant  drop  in  mortality  at  1  year  (19%  vs  26%,  respec-
ively)  and  at  3.4  years  (33%  vs  44%,  respectively)  [29]. As
he  DIGAMI  study  also  included  outpatient  insulin  therapy,
he  isolated  effect  of  in-hospital  glycaemic  control  could
ot  be  easily  assessed.  However,  an  observational  study  con-
ucted  in  50,205  patients  hospitalized  for  ACS  showed  that
nsulin  treatment  was  beneﬁcial  in  patients  with  no  history
f  diabetes,  but  an  admission  glycaemia  greater  or  equal
o  200  mg/dL  (11.1  mmol/L)  [30]. In  that  study,  patients
ho  were  not  treated  with  insulin  had,  after  adjusting  for
onfounding  factors,  signiﬁcantly  increased  relative  risks  of
eath—–speciﬁcally,  56%  at  7  days  and  51%  at  30  days.
Nevertheless,  the  beneﬁt  of  intensive  insulin  treatment
as  not  been  observed  in  other  studies.  In  the  DIGAMI-2
rial,  patients  with  type  2  diabetes  and  acute  MI  were  ran-
omly  assigned  to  receive  one  of  three  glucose-management
trategies:  group  1,  inpatient  insulin  infusion/outpatient
ntensive  subcutaneous  insulin  therapy;  group  2,  inpatient
nsulin  infusion/outpatient  standard  treatment;  and  group
,  inpatient/outpatient  standard  glucose  management  [31].
lthough  it  was  anticipated  that  mortality  rates  would
e  lowest  for  group  1,  in  fact,  the  rates  were  similar
cross  all  three  groups.  However,  the  study  had  several
roblems,  including  similar  glycaemic  control  in  all  three
roups,  low  event  rates  and  a  lack  of  statistical  power
ue  to  poor  recruitment.  In  the  Hyperglycemia:  Intensive
nsulin  Infusion  in  Infarction  (HI-5)  study  of  240  patients
ith  acute  MI  and  diabetes  or  admission  glycaemia  greater
r  equal  to  140  mg/dL  (7.8  mmol/L),  mortality  in  hospital
t  3  and  6  months  did  not  differ  between  treatment  with
nsulin/dextrose  infusion  for  at  least  24  h  and  conventional
herapy  [32]. However,  the  HI-5  study  was  seriously  ﬂawed
y  a  too-small  number  of  patients,  lack  of  blinding,  main-
enance  of  glycaemic  control  for  only  24  h,  and  failure  to
ttain  a  signiﬁcant  difference  in  mean  24-h  blood  glucose
etween  the  intensive  therapy  and  control  groups  [32]. Sub-
et  analyses  found  that  in-hospital  mortality  rates  (0%  vs  7%),
nd  at  3  and  6  months  (2%  vs  11%),  were  considerably  lower
n  patients  with  mean  blood  glucose  levels  less  or  equal  to
44  mg/dL  (8.0  mmol/L)  during  the  ﬁrst  24  h.
A  meta-analysis  of  15  randomized  trials  (10,140  patients)
omparing  the  effect  of  tight  glucose  control  [glycaemic
2 B.  Vergès  et  al.
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CONSENSUS  STATEMENT  (DIABETES  CARE  IN
INTENSIVE  CARE  UNIT)
1. In  cases  of  unknown  diabetes,  continuous  insulin
treatment  has  to  be  initiated  when  admission  blood
glucose  level  is  greater  or  equal  to  180  mg/dL
(10.0  mmol/L;  Level  A).
2.  In  cases  of  previously  known  diabetes:
•  continuous  insulin  treatment  has  to  be  initiated
when  the  admission  blood  glucose  is  greater
or  equal  to  180  mg/dL  (10.0  mmol/L)  and/or
preprandial  glucose  is  greater  or  equal  to
140  mg/dL  (7.77  mmol/L)  during  follow-up  in  an
intensive  care  unit  (Level  A);
•  all  other  antidiabetic  treatments  should  be
stopped  during  hospitalization  in  a  cardiology
intensive  care  unit  (professional  agreement);
• if  the  patient  had  known  diabetes  treated
with  insulin  and  admission  blood  glucose  less
than  180  mg/dL  (10.0  mmol/L)  and/or  preprandial
glucose  less  than  140  mg/dL  (7.7  mmol/L)  during
follow-up  in  an  intensive  care  unit,  the  insulin
regimen  used  prior  to  hospitalization  can  be
continued  (professional  agreement).
3. A  blood  glucose  target  of  140  to  180  mg/dL  (7.7
to  10  mmol/L)  is  recommended  for  most  patients,
rather  than  the  more  stringent  target  of  110  to
140  mg/dL  (6.1  to  7.7  mmol/L;  Level  A).
4. A  blood  glucose  target  less  than  110  mg/dL
(6.1  mmol/L)  is  not  recommended  (Level  A).
5.  The  recommended  insulin  treatment  is  continuous
IV  insulin  infusion  with  a  preprandial  bolus
(see  proposed  protocol  below).  Insulin  dosage
is  to  be  adapted  according  to  capillary  glucose
measurements  (Level  A).
6.  In  patients  on  continuous  IV  insulin  infusion,  blood
(capillary)  glucose  is  to  be  monitored  1  h  after
initiation,  then  every  2  h  (Level  A).
7.  In  hyperglycaemic/diabetic  patients  not  on
continuous  IV  insulin  infusion,  blood  (capillary)
glucose  is  to  be  monitored  before  each  meal,
2  h  after  meals  and  at  bedtime  (professional
agreement).
8.  In  cardiology  intensive  care  units,  the  treatment  of
diabetes  that  requires  insulin  needs  to  be  performed
by  an  experienced  team  including  a  diabetologist
(professional  agreement).
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arget  less  or  equal  to  150  mg/dL  (8.3  mmol/L)]  with  less
tringent  glycaemic  control  in  ICU  patients  showed  that  mor-
ality  in  patients  with  tight  glucose  control  was  similar  to
hat  of  patients  with  less  stringent  glycaemic  control  [26.7%
s  25.6%,  respectively;  not  signiﬁcant  (NS)]  [33].
.2. Risk of hypoglycaemia
ntensive  insulin  treatment  has  been  associated  with  an
ncreased  risk  of  hypoglycaemia  in  up  to  19%  of  patients
hen  deﬁned  as  glycaemia  less  than  40  mg/dL  (2.2  mmol/L),
nd  in  up  to  32%  of  patients  when  deﬁned  as  glycaemia
ess  than  60  mg/dL  (3.3  mmol/L)  [34]. Hypoglycaemia  can
ead  to  seizures,  brain  damage,  depression,  cardiac  arrhyth-
ias  and  death  [35]. The  risk  of  hypoglycaemia  was
lso  evaluated  in  the  large  multicentre  Normoglycemia  in
ntensive  Care  Evaluation—Survival  using  Glucose  Algorithm
egulation  (NICE—SUGAR)  trial,  which  randomly  assigned
104  ICU  patients  to  either  intensive  insulin  treatment
glycaemic  target  of  81—108  mg/dL  (4.5—6  mmol/L)]  or  con-
entional  glucose  control  [glycaemic  target  of  <  180  mg/dL
<  10  mmol/L)]  [36]. Intensive  insulin  treatment  compared
ith  conventional  glucose  control  led  to  signiﬁcantly
ower  time-weighted  glycaemia  [115  vs  144  mg/dL  (6.2  vs
.9  mmol/L)],  and  signiﬁcant  increases  in  severe  hypogly-
aemia  (6.8%  vs  0.5%)  and  90-day  mortality  (27.5%  vs  24.9%,
R:  1.14,  95%  CI:  1.02—1.28)  [36]. The  Efﬁcacy  of  Volume
ubstitution  and  Insulin  Therapy  in  Severe  Sepsis  (VISEP)
rial,  comparing  intensive  insulin  treatment  [glycaemic
arget  of  80—110  mg/dL  (4.4—6.1  mmol/L)]  with  conven-
ional  glucose  control  [glycaemic  target  of  180—200  mg/dL
10—11.1  mmol/L)]  in  ICU  patients  with  severe  sepsis,  was
topped  early  because  the  intensive  insulin  treatment  sig-
iﬁcantly  increased  rates  of  hypoglycaemia  (12.1%  vs  2.1%)
nd  serious  adverse  events  (10.9%  vs  5.2%)  [37]. The  multi-
entre  Glucontrol  trial,  involving  1101  critically  ill  patients,
howed  that  intensive  insulin  treatment  versus  conventional
reatment  induced  a  higher  rate  of  hypoglycaemia  (8.7%
s  2.7%),  and  a  non-signiﬁcant  trend  towards  higher  28-
ay  mortality  and  in-hospital  mortality  [38]. A  retrospective
tudy  of  7820  patients  hospitalized  for  acute  MI  reported
hat  hypoglycaemia  was  associated  with  increased  mortal-
ty  in  patients  not  treated  with  insulin,  but  not  in  patients
reated  with  insulin  [39].
Thus,  so  far,  the  data  in  the  literature  show  that,  in
opulations  of  critically  ill  patients,  intensive  insulin  treat-
ent  [glycaemic  target  of  80—110  mg/dL  (4.4—6.1  mmol/L)]
ncreases  the  incidence  of  severe  hypoglycaemia  and  may
ncrease  mortality  compared  with  the  more  permissive  blood
lucose  ranges  of  140—180  mg/dL  (7.8—10  mmol/L).
.3. Which insulin infusion protocol?
ntravenous  infusion  of  insulin  is  usually  recommended  with
 concomitant  infusion  of  glucose.  However,  a  wide  variabil-
ty  in  the  insulin  infusion  protocols  used  in  critical  care  has
een  reported,  with  differences  in  initial  insulin  dose,  titra-
ion  of  insulin,  use  of  insulin  bolus,  glycaemic  targets  and
ethods  for  adjusting  insulin  protocols  [40]. This  reﬂects
he  lack  of  consensus  in  the  delivery  of  intravenous  insulin
n  critical  care.
F
m
aA  protocol  for  insulin  administration  in  a  cardiology  inten-
ive  care  unit  and  a  protocol  for  transition  from  intravenous
o  subcutaneous  insulin  are  given  in  the  Addendum.
. Diabetes care during hospitalization in
 post-intensive care unitollowing  the  period  in  the  ICU,  insulin  treatment  is  not
andatory  for  every  patient  with  diabetes,  and  other  antidi-
betic  treatments  may  be  considered.  The  choice  of  optimal
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treatment,  however,  depends  on  the  metabolic  proﬁle  of
the  patient.  In  cases  of  uncontrolled  diabetes  (HbA1c ≥  8%),
referral  to  a  diabetologist  is  recommended.
4.1. Metformin
In  the  United  Kingdom  Prospective  Diabetes  Study  (UKPDS),
monotherapy  with  metformin  in  diabetic  patients  with  a
body  mass  index  (BMI)  greater  or  equal  to  25  kg/m2 was
associated  with  signiﬁcant  decreases  in  overall  mortality
(−36%)  and  MI  (−39%),  and  a  non-signiﬁcant  decrease  in
stroke  (−41%),  compared  with  treatment  with  sulphonylurea
or  insulin  [41]. However,  the  participants  in  the  UKPDS  were
newly  diagnosed  type  2  diabetes  patients  mostly  in  primary
prevention.  Little  data  on  metformin  after  MI  are  available,
whereas  many  case—control  studies  have  shown  reductions
in  cardiovascular  morbidity  and  mortality  with  metformin
(vs  sulphonylurea)  [42]. One  meta-analysis  showed  that  met-
formin  treatment  was  associated  with  a  signiﬁcant  decrease
in  cardiovascular  mortality  (OR:  0.74;  95%  CI:  0.62—0.89)
compared  with  other  antidiabetic  treatments  [43]. In  the
19,699  patients  with  type  2  diabetes  and  a  history  of  cardio-
vascular  disease  in  the  Reduction  of  Atherothrombosis  for
Continued  Health  (REACH)  registry,  a  signiﬁcant  reduction
in  2-year  mortality  was  observed  with  metformin  (adjusted
HR:  0.76;  P  <  0.001)  [44]. This  beneﬁt  was  also  observed  in
patients  with  renal  failure  or  a  history  of  congestive  heart
failure,  usually  considered  contraindications  for  metformin
[44].  In  the  DIGAMI-2  study,  metformin  was  associated  with  a
signiﬁcant  37%  reduction  in  non-fatal  cardiovascular  events
at  2  years  (P  =  0.03)  [45], and  signiﬁcant  decreases  in  all-
cause  mortality  (P  =  0.01)  and  cancer  mortality  (P  =  0.02)  at
4  years  [46]. Although  no  prospective  studies  with  metformin
have  been  performed  in  patients  with  type  2  diabetes  after
ACS,  data  from  case—control  studies  and  the  DIGAMI-2  trial
suggest  that  the  use  of  metformin  in  such  situations  may
be  recommended.  In  a  Danish  study  of  10,920  patients  hos-
pitalized  for  heart  failure,  treatment  with  metformin  was
associated  with  a  low  risk  of  mortality  compared  with  treat-
ment  with  sulphonylurea  or  insulin  [47]. However,  its  use  is
not  recommended  in  cases  of  uncontrolled  cardiac  or  renal
failure.
4.2. Sulphonylureas
Results  from  the  University  Group  Diabetes  Program  (UGDP)
trial  showed  a  potential  increase  in  cardiovascular  risk  in
patients  treated  with  ﬁrst-generation  sulphonylureas  [48].
Controversial  experimental  studies  have  suggested  that,  as
sulphonylurea  binds  to  K+  channels,  it  could  impair  myocar-
dial  preconditioning,  a  natural  cardioprotective  mechanism.
In  experimental  models  of  ischaemia,  coronary  artery
vasodilation  was  impaired  in  animals  given  sulphonylurea
treatment  [49].
However,  several  observational  studies  failed  to  estab-
lish  an  association  between  sulphonylurea  treatment  and
the  occurrence  of  ACS,  although  a  recent  observational
study  suggested  a  greater  incidence  of  cardiovascular  death
and  congestive  heart  failure  in  patients  taking  sulpho-
nylurea  compared  with  those  taking  metformin  [50]. In
the  UKPDS  and  Action  in  Diabetes  and  Vascular  Dis-
ease:  Preterax  and  Diamicron  Modiﬁed  Release  Controlled
t
h
C
lc  patient  245
valuation  (ADVANCE)  trial,  no  increase  in  cardiovascular
isk  was  found  when  treatment  was  intensiﬁed  by  sulpho-
ylurea  [51,52]  and,  in  an  earlier  study,  no  association  was
eported  between  the  size  of  MI  and  previous  treatment
ith  glibenclamide  [53]. On  the  other  hand,  observational
tudies  in  patients  who  had  undergone  coronary  angioplasty
fter  MI  have  shown  an  increase  in  cardiovascular  mortality
n  those  using  sulphonylurea  that  was  attributed  to  dete-
ioration  of  preconditioning  [54]. One  case—control  study
eported  a  30%  increase  in  cardiovascular  death  following
I  in  patients  treated  with  ﬁrst-generation  sulphonylureas
nd  with  glibenclamide  [55], although  several  recent  phar-
acoepidemiological  studies  failed  to  ﬁnd  any  increase  in
ardiovascular  risk  with  second-generation  sulphonylureas
fter  ACS  [56—58]. Nevertheless,  in  the  Danish  registry,
ardiovascular  risk  was  higher  in  patients  treated  with
ulphonylureas,  with  the  exception  of  gliclazide,  than  with
etformin  [59]. Data  from  the  sulphamide-treated  patients
n  the  French  Registry  of  Acute  ST-Elevation  and  Non-ST-
levation  Myocardial  Infarction  (FAST-MI)  have  shown  that
n-hospital  mortality  was  signiﬁcantly  lower  in  patients
eceiving  pancreatic  cell-speciﬁc  sulphonylurea  (gliclazide
r  glimepiride;  2.7%)  compared  with  glibenclamide  (7.5%;
 =  0.019),  indicating  potential  differences  among  the  vari-
us  sulphonylurea  drugs  [57].
.3. Glinides
nly  limited  and/or  indirect  data  are  available  on  glin-
des  and  cardiovascular  risk.  In  the  Danish  registry,  no  ﬁrm
onclusions  could  be  drawn  due  to  a  lack  of  statistical
ower,  although  there  was  a  trend  towards  greater  cardio-
ascular  risk  with  glinides  than  with  metformin  [OR:  1.29
0.86—1.94)]  [59]. In  the  Nateglinide  and  Valsartan  Impaired
lucose  Tolerance  Outcomes  Research  (NAVIGATOR),  no
ncreases  in  cardiovascular  morbidity  and/or  cardiovascu-
ar  mortality  were  found  with  nateglinide  compared  with  a
lacebo  [60].
.4. Acarbose
n  experimental  models  of  ischaemia  reperfusion,  a  decrease
n  the  size  of  necrotic  lesions  was  reported  with  acarbose
61], and  type  2  diabetes  patients  treated  with  acarbose
howed  greater  improvements  in  endothelial  function  in  the
ostprandial  phase  than  those  treated  with  nateglinide  [62].
 lower  risk  of  cardiovascular  events  was  also  observed  in
lucose-intolerant  patients  treated  with  acarbose  vs  placebo
n  the  STOP-NIDDM  trial  [63]. In  addition,  treatment  with
carbose  was  associated  with  a  lower  risk  of  MI  in  a  meta-
nalysis  of  seven  clinical  trials  involving  patients  with  type
 diabetes  (HR:  0.36,  95%  CI:  0.16—0.80;  P  =  0.012)  [64].
.5. Pioglitazone
ioglitazone  is  a  peroxisome  proliferator-activated
eceptor-gamma  (PPAR-) agonist  receptor  that  improves
nsulin  sensitivity  and  glucose  control,  decreases  plasma
riglycerides  and  increases  HDL  cholesterol.  Several  studies
ave  shown  a  reduction  in  inﬂammatory  markers,  such  as
-reactive  protein  (CRP),  and  improvement  in  endothe-
ial  dysfunction  in  patients  taking  pioglitazone.  In  the
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i46  
rospective  Pioglitazone  Clinical  Trial  in  Macrovascular
vents  (PROactive)  of  patients  with  type  2  diabetes  and
ardiovascular  disease,  pioglitazone  (vs  placebo)  induced  a
on-signiﬁcant  reduction  in  the  primary  endpoint,  including
eg  amputation  and  leg  revascularization,  but  also  led
o  a  signiﬁcant  reduction  in  major  cardiovascular  events
−16%)  [65]  and  a  signiﬁcant  28%  reduction  in  recurrent
I  in  patients  with  a  history  of  MI  [66]. A  meta-analysis
onﬁrmed  the  beneﬁts  of  pioglitazone  for  ischaemic
ardiovascular  events,  but  also  showed  an  increase  in
eart  failure  [67]. Another  meta-analysis  of  controlled
tudies  of  diabetic  patients  with  heart  failure  showed  that
he  glitazones  were  associated  with  an  increased  risk  of
ospital  admission  for  heart  failure,  but  also  with  reduced
ll-cause  mortality  [68]. In  the  PROactive,  the  incidence
f  heart  failure  was  increased  with  pioglitazone  vs  placebo
7.5%  vs  5.2%,  respectively),  but  with  no  increase  in
eart-failure-induced  mortality  (1.4%  vs  0.9%,  respectively)
65].
All  the  available  data  conﬁrm  the  global  cardiovascu-
ar  beneﬁt  of  pioglitazone  in  patients  with  type  2  diabetes
nd  a  history  of  MI,  with  a  signiﬁcant  reduction  in  the
isk  of  a  recurrent  event.  One  complementary  analysis  sug-
ested  that  the  cardiovascular  beneﬁt  of  pioglitazone  in
he  PROactive  may  have  partly  been  due  to  the  increase
n  plasma  HDL  cholesterol  [69]. However,  the  use  of  piogli-
azone  in  France  has  recently  been  suspended  due  to
oncerns  over  bladder-cancer  risks,  although  pioglitazone
s  still  available  in  most  countries  worldwide,  and  has  the
pproval  of  European  (European  Medicines  Agency,  EMEA)
nd  American  (Food  and  Drug  Administration,  FDA)  drugs
gencies.
.6. Glucagon-like peptide (GLP)-1 agonists
LP-1  agonists  reduce  hyperglycaemia  by  enhancing
lucose-induced  insulin  secretion  and  inhibiting  glucagon
roduction.  Experimental  and  clinical  studies  have
uggested  that  GLP-1  can  protect  the  heart  against
schaemia/reperfusion  injury,  and  improve  left-ventricle
ontractility  and  endothelial  function  [70—72].
A  recent  analysis  of  data  from  health-insurance  agencies
uggests,  after  adjusting  for  potential  confounding  fac-
ors,  cardiovascular  beneﬁt  with  exenatide  [adjusted  HR:
.81  (0.68—0.95);  P  =  0.01]  [73], although  patients  with  a
ecent  cardiovascular  event  were  excluded  from  the  study.
n  a  meta-analysis  of  12  controlled  randomized  studies  with
xenatide,  including  diabetes  patients  with  a  history  of
ardiovascular  disease,  a  non-signiﬁcant  decrease  in  the
respeciﬁed  endpoint  [cardiovascular  death,  MI,  ischaemic
troke,  revascularization;  OR:  0.70  (0.38—1.31);  P  >  0.05]
as  observed  [74]. Analysis  of  the  pooled  data  from  clin-
cal  trials  with  liraglutide  showed  no  signiﬁcant  effect  of
iraglutide  on  cardiovascular  events  [75]. A  study  compar-
ng  exenatide  (10  g  BID)  with  liraglutide  (1.8  mg  once  daily)
howed  greater  reductions  with  liraglutide  in  HbA1c (−1.12%
s  −0.79%;  P  <  0.0001)  and  in  triglycerides,  although  no  dif-
erences  between  the  two  drugs  were  noted  in  body  weight,
lood  pressure,  low-density  lipoprotein  (LDL)  or  HDL  choles-
erol,  or  incidence  of  cardiovascular  events  [76]. When
ata  from  clinical  trials  of  both  exenatide  and  liraglutide
ere  combined,  a  signiﬁcant  reduction  in  the  risk  of  major
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ardiovascular  events  was  observed  versus  placebo  [OR:  0.46
0.26—0.83);  P  =  0.009],  but  not  versus  active  antidiabetic
reatment  [77].
.7. Dipeptidyl peptidase (DPP)-4 inhibitors
PP-4  inhibitors  reduce  GLP-1  enzymatic  degradation,  thus
eading  to  moderate  increases  in  its  plasma  concentration.
ooled  analysis  of  the  data  from  19  clinical  trials  with
itagliptin  vs  a  placebo  or  other  active  antidiabetic  treat-
ents  showed  non-signiﬁcant  differences  in  the  incidence
f  major  cardiovascular  events  [78]. In  an  analysis  of  the
ooled  data  from  25  clinical  trials  with  vildagliptin,  the
elative  risk  of  major  cardiovascular  events  (cardiovascu-
ar  death,  MI,  stroke)  compared  with  controls  (a  placebo  or
ctive  antidiabetic  treatment)  was  0.88  (0.37—2.11),  and
.78  (0.51—1.19)  in  the  subgroup  of  patients  in  secondary
revention  [79]. In  an  analysis  of  pooled  data  from  tri-
ls  of  saxagliptin,  but  with  a  limited  number  of  patients,
axagliptin  was  shown  to  be  associated  with  a  lower  risk
f  cardiovascular  events  [OR:  0.43  (0.23—0.80)]  [80]. A
eta-analysis  showed  a  non-signiﬁcant  decrease  of  the
isk  of  cardiovascular  events  and  all-cause  death  with  DPP
nhibitors  [81].
CONSENSUS  STATEMENT  (DIABETES  CARE  IN  A  POST
INTENSIVE  CARE  UNIT)
1. Metformin  is  not  contraindicated  after  ACS  in  the
absence  of  renal  failure  (professional  agreement).
2. Following  ACS,  due  to  the  increase  in  cardiovascular
risk  reported  in  observational  studies,  it  is
recommended  to  not  use  a  ﬁrst-generation
sulphonylurea  or  glibenclamide  (Level  C).
3. Glinides  are  not  contraindicated  following  ACS
(professional  agreement).
4. Acarbose  may  be  used  following  ACS  when  needed,
according  to  the  metabolic  phenotype  of  the
patient  (predominant  postprandial  hyperglycaemia)
(professional  agreement).
5.  Pioglitazone,  when  available,  is  not  contraindicated
following  ACS.  It  must  not  be  used  in  cases  of
congestive  heart  failure  or  when  LVEF  is  less  than
45%  (professional  agreement).
6.  GLP-1  agonists  are  not  contraindicated  following
ACS  (professional  agreement).
7.  DPP-4  inhibitors  are  not  contraindicated  following
ACS  (professional  agreement).
. Diabetes care during cardiac
ehabilitation
 comprehensive  cardiac  rehabilitation  programme  should
nclude  supervised  physical  activity  after  cardiac  assess-
ent,  education  on  all  cardiovascular  risk  factors  (including
iabetes),  promotion  of  physical  activity  as  a  therapeutic
ntervention,  psychological  support,  nutritional  coun-
elling  and  planning  of  long-term  regular  physical  activity
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CONSENSUS  STATEMENT  (DURING  CARDIAC
REHABILITATION)
1.  Cardiac  rehabilitation  decreases  total  and
cardiovascular  morbidity  and  mortality  in  patients
after  ACS  (Level  A).  Although  no  outcome
trials  speciﬁcally  for  the  diabetic  population
are  available,  we  may  expect  that  cardiac
rehabilitation  is  likely  to  induce  similar  beneﬁts  in
patients  with  diabetes.
2.  Cardiac  rehabilitation  is  an  opportunity  to  show
patients  the  beneﬁts  of  regular  physical  activity
not  only  for  cardiovascular  prevention,  but  also
for  improving  glycaemic  control  and  preventing
diabetes  (Level  A).
3.  Blood  glucose  should  be  checked  before  exercise
in  every  patient  with  diabetes.  In  addition,
blood  glucose  testing  should  also  be  performed
at  the  end,  and  4—6  h  after,  each  physical-
activity  session  in  patients  treated  with  insulin  or
insulin  secretagogues  (sulphonylureas  or  glinides)
to  reduce  the  risk  of  hypoglycaemic  episodes
(professional  agreement).
4. When  blood  glucose  before  exercise  is  greater
than  250  mg/dL  (13.9  mmol/L),  ketonuria  needs
to  be  checked.  If  the  patient  is  without  ketosis,
feeling  well  and  properly  hydrated,  then  physical
activity  can  be  performed  with  caution,  with
regular  capillary  blood  testing  recommended  at
least  hourly  during  the  training  session  (professional
agreement).
5.  During  cardiac  rehabilitation,  the  patient  should
be  referred  to  a  diabetologist/diabetology  team
in  the  following  cases:  uncontrolled  diabetes  with
signiﬁcant  hyperglycaemia  (HbA1c >  8%);  and/or
severe/repeated  hypoglycaemia  (professional
agreement).
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carbohydrates  in  the  diet  is  crucial  for  glycaemic  control
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following  cardiac  rehabilitation.  Cardiac  rehabilitation
decreases  all-cause  and  cardiovascular  morbidity  and  mor-
tality  in  patients  after  ACS  [82]. Peak  exercise  capacity,
measured  in  metabolic  equivalents  (MET),  is  known  to  be  an
important  prognostic  factor.  Each  1-MET  increase  in  exercise
capacity  conferred  a  12%  improvement  in  survival  in  several
subgroups,  including  type  2  diabetes  patients  [83]. However,
it  has  also  been  shown  that  hyperglycaemia  during  cardiac
rehabilitation  is  associated  with  a  smaller  improvement  in
exercise  capacity  [84].
Nevertheless,  cardiac  rehabilitation  also  improves  psy-
chological  well-being  [85], patients’  adherence  to  pharma-
cological  advice  and  lifestyle  modiﬁcations,  and  patients’
motivation  for  future  long-term  physical  activity.  In  addi-
tion,  it  is  a  cost-effective  intervention  after  an  acute
coronary  event  [86].
Many  studies  have  shown  the  beneﬁt  of  physical
activity  for  glycaemic  control,  for  reductions  in  weight
and  visceral  adipose  tissue,  and  for  insulin  sensitivity
[87].  Also,  regular  physical  activity  in  patients  with  IGT
can  prevent  or  delay  the  onset  of  type  2  diabetes
[88,89].
Cardiac  rehabilitation  reduces  depression  in  diabetic
patients  and  increases  patients’  motivation  for  lifestyle
modiﬁcations  [85]. It  should  be  started  soon  after  clinical
stabilization  and  the  patient’s  assessment  by  a  submaximum
exercise  stress  test.  The  exercise  component  of  the  pro-
gramme,  prescribed  by  a  cardiologist,  is  a  combination  of
endurance  and  light  resistance  training  sessions  associated
with,  for  example,  ﬂexibility  training,  chest  physiother-
apy  and  hydrotherapy.  It  should  be  individualized  for  each
patient.
During  cardiac  rehabilitation,  blood  glucose  levels  need
to  be  controlled  regularly  because  of  the  effect  of  phys-
ical  activity  on  glucose  metabolism.  It  has  been  shown
that  blood  glucose  reduction  correlates  with  the  duration
of  the  aerobic  physical-training  session  and  lasts  up  to
30  h  following  exercise  [90,91].  Self-monitoring  of  blood
glucose  (SMBG)  provides  a  potential  tool  for  controlling
blood  glucose,  and  preventing  signiﬁcant  hypoglycaemia
during  and  after  physical  activity,  particularly  in  patients
treated  with  insulin  and/or  insulin-secreting  agents  [92].
Furthermore,  SMBG  can  be  helpful  for  adjusting  antidia-
betic  treatments,  if  necessary,  and  for  educational  purposes
[93].
Indeed,  cardiac  rehabilitation  represents  a  unique  oppor-
tunity  to  refer  a  patient  for  education  covering  not  only  the
usual  information  on  diabetes,  but  also  the  beneﬁts  of  phys-
ical  activity  to  diabetes  and  the  management  of  diabetes
during  physical  activity  (with  the  help  of  SMBG).  Such  edu-
cation  reinforces  patients’  empowerment  [94]. Patients  with
and  without  diabetes  should  also  be  given  nutritional  coun-
selling  to  prevent  cardiovascular  disease.  In  patients  with
diabetes,  additional  information  should  be  given  on  weight
reduction,  and  the  prevention  and  treatment  of  hypogly-
caemic  episodes  [95]. Cardiac  rehabilitation  provides  an
opportunity  to  optimize  the  treatment  of  diabetes,  and
referral  to  a  diabetologist/diabetology  team  can  also  be
useful  (see  below)  [96].
So far,  no  data  are  available  for  cardiac  rehabilitation  in
patients  with  diabetic  complications  (peripheral  neuropa-
thy,  retinopathy  and  nephropathy). d. Nutrition/Diet
utrition  plays  an  important  role  in  the  treatment  of  dia-
etes.  It  is  important  for  optimal  glycaemic  control,  and
lso  plays  an  important  role  in  the  primary  and  secondary
revention  of  cardiovascular  disease  [97]. Nutritional  treat-
ent  needs  to  be  discussed  with  the  diabetic  patient,  with
ultural  and  ethnical  speciﬁcities  taken  into  account.  The
ietary  programme  should  be  adapted  to  each  patient.  It  has
lso  been  conﬁrmed  that  nutritional  education  provided  by
are  providers  who  are  familiar  with  diabetes  and  nutritional
ardiovascular  prevention,  and  trained  in  patients’  educa-
ion,  leads  to  beneﬁcial  results  in  the  control  of  glycaemia
nd  cardiovascular  risk  factors  [98—100].
A  balance  between  ingested  carbohydrates  and  insulin
endogenous  or  therapeutically  administered)  is  critical  for
ostprandial  blood  glucose  control.  Thus,  the  proportion  ofrate  in  a  meal  is  the  major  determinant  of  postprandial
2 B.  Vergès  et  al.
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CONSENSUS  STATEMENT  (NUTRITION/DIET)
During  hospitalization:
1.  There  is  no  speciﬁc  recommended  carbohydrate
level  for  patients  with  diabetes.  The  proportion
of  carbohydrate  in  the  diet  does  not  need  to  be
different  from  that  for  non-diabetics.  A  minimum
carbohydrate  amount  of  150  g/day  is  recommended
(Level  A).
2.  In  the  absence  of  a  diabetology  team  working  in
the  cardiology  ICU,  it  is  recommended  to  use  a
ﬁxed  carbohydrate  dose  for  each  meal  (professional
agreement).
3. Patients  with  diabetes  are  recommended  to  have
three  meals  a  day  (in  the  absence  of  a  concomitant
procedure;  Level  A).
4.  Unnecessary  fasting  should  be  avoided  (professional
agreement).
5. Low  glycaemic-index  (GI)  foods  should  be  preferred
over  high  GI  foods  (Level  B).
6. In  general,  sucrose  should  be  avoided  (professional
agreement).
7. Sucrose  is  not  recommended  between  meals
with  the  exception  of  hypoglycaemia  (professional
agreement).
8. For  patients  who  wish  to  have  sucrose,  it should  be
included  in  a  meal  and  replace  an  equivalent  dose
of  carbohydrate  (Level  A).
At  discharge,  speciﬁc  recommendations  for  coronary
artery  disease  prevention:
1.  Saturated  fat  should  be  limited  to  less  than  10%  of
total  energy  intake  and,  if  possible,  be  less  than  7%
(Level  A).
2.  Trans  fatty  acids  should  be  avoided  (Level  A).
3.  A  Mediterranean-style  diet  rich  in  fruits,  vegetables
and  monounsaturated  fatty  acids  is  recommended
(Level  A).
4.  In  cases  of  overt  hypertriglyceridaemia,  the  patient
should  be  referred  to  a  dietitian  (professional
agreement).
5.  Consultation  with  a  dietitian  is  recommended  in
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lycaemia  [101,102].  In  patients  with  diabetes  treated
ith  diet  only  and/or  oral  antidiabetic  agents  and/or  ﬁxed
nsulin  doses,  it  is  usually  recommended  to  have,  for  each
eal  (breakfast,  lunch,  dinner),  a  reproducible  carbohy-
rate  ratio  from  day  to  day.  In  patients  treated  with  rapid
nsulin  before  each  meal,  the  quantity  of  carbohydrate  in
he  meal  can  be  modiﬁed,  but  the  dose  of  insulin  for  the
eal  should  then  be  adjusted  accordingly.  To  do  this,  the
atient  needs  to  be  educated  by  a  trained  diabetology
eam.
For  the  prevention  of  coronary  artery  disease,  it  is
ecommended  to  reduce  saturated  fats,  trans  fatty  acids
nd  sodium,  and  to  adopt  a  Mediterranean-style  diet  (rich
n  monounsaturated  fats,  omega-3  fatty  acids,  fruits  and
egetables).  All  these  nutritional  recommendations  have
een  shown  to  reduce  cardiovascular  risk  factors  (mostly
ipids  and  high  blood  pressure)  in  patients  with  diabetes
103—105].
In  patients  with  type  2  diabetes,  hypertriglyceridaemia
s  frequently  seen.  In  situations  of  frank  hypertriglyceri-
aemia  (>  400  mg/dL),  fructose  (which  promotes  hepatic
riglyceride  production)  should  be  restricted  and  the  con-
umption  of  fruits  limited.  After  ACS,  consultation  with
 dietitian  is  mandatory  in  patients  with  overt  hyper-
riglyceridaemia.  As  a  matter  of  fact,  consultation  with  a
ietitian  may  be  of  value  for  all  patients  with  diabetes
fter  ACS  to  obtain  dietary  recommendations  speciﬁcally
or  diabetes,  prevention  of  atherosclerosis  and,  if  neces-
ary,  weight  reduction.  The  nutritional  recommendations
resented  here  are  limited  to  the  ACS  period,  and  do  not
mbrace  all  of  the  dietary  recommendations  for  patients
ith  diabetes.
. When should a patient with diabetes be
eferred to a diabetologist?
everal  consensus  statements  have  emphasized  the  beneﬁts
f  referring  a  patient  to  a  diabetologist  during  hospitaliza-
ion  for  conditions  other  than  diabetes  [106—108].  Referral
o  a  diabetologist  during  hospitalization  for  ACS  is  likely  to
onfer  substantial  beneﬁts  to  patients  with  diabetes.  Hospi-
alization  for  ACS  provides  a  unique  opportunity  to  optimize
he  treatment  of  diabetes  and  to  educate  patients  in  dia-
etes  self-management  [109].
It is  advisable,  before  discharge  from  hospital,  to  set  up
 strategy  for  optimal  outpatient  glucose  control  in  patients
ith  established  diabetes  or  newly  diagnosed  diabetes.  It  is
enerally  advisable  to  refer  a  patient  with  diabetes  to  a  dia-
etologist  before  discharge  or  within  1  month  of  discharge
108].
The  importance  of  patients’  education  is  emphasized
n  the  ADA  and  American  Association  of  Clinical  Endocri-
ologists  (AACE)  consensus  statement  [107]. Because  the
ength  of  hospital  stay  for  ACS  is  usually  short,  during  hos-
italization,  it  is  recommended  to  limit  diabetes-related
ducation  to  an  inventory  of  basic  ‘survival  skills’  (level  of
nderstanding  related  to  the  diagnosis  of  diabetes,  SMBG
nd  explanation  of  home  glycaemic  goals;  deﬁnition,  recog-
ition,  treatment  and  prevention  of  hyperglycaemia  and
ypoglycaemia;  information  on  diet;  when  and  how  to  take
t
a
t
cdiabetes  patients  after  ACS.
lucose-lowering  medications,  including  the  administration
f  insulin;  sick-day  management;  and  identiﬁcation  of  a
ealthcare  provider  responsible  for  diabetes  care  after
ischarge).  Several  studies  have  shown  that  medication
rrors  and  adverse  drug  events  are  linked  to  poor  communi-
ation  of  instructions  to  the  patient  at  the  time  of  discharge
110,111].  Thus,  clear  instructions  at  discharge  and  during
utpatient  care  are  necessary  to  provide  a  reference  for
atients  and  their  outpatient  providers.  It  has  also  been
hown  that  an  insulin-speciﬁc  discharge  instruction  form  can
rovide  greater  clarity  and  more  consistent  instructions  for
nsulin  dosing  and  SMBG  in  comparison  to  a  generic  hospi-
al  discharge  form  [112]. Several  studies  have  shown  that
n  educational  programme  on  diabetes  during  hospitaliza-
ion  leads  to  better  outcomes,  such  as  improved  glycaemic
ontrol  [113,114],  fewer  hospitalizations  [113,114],  fewer
betic  patient  249
4.  Referral  to  a  diabetologist  during  cardiac
rehabilitation:  the  patient  should  be  referred
to  a  diabetologist  in  the  following  situation:
•  uncontrolled  diabetes  with  signiﬁcant
hyperglycaemia
•  and/or  severe/repeated  hypoglycaemia
(professional  agreement).
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episodes  of  ketoacidosis  [114]  and  reduced  length  of  hos-
pital  stays  [115]. Moreover,  in  patients  hospitalized  in
medical  and  surgical  cardiac  care  units,  an  interven-
tional  programme  on  diabetes,  including  clear  self-care
instructions  before  discharge,  signiﬁcantly  decreased  the
frequency  of  prolonged  and  severe  hyperglycaemia,  and
the  frequency  of  nosocomial  infections  [116]. Thus,  a clear
educational  programme  covering  the  basic  points  of  dia-
betes  is  highly  recommended  before  discharge,  whether
performed  by  a  diabetologist  and/or  a  diabetes  educa-
tor.
In  fact,  diabetes  care  delivered  by  an  endocrinolo-
gist/diabetologist  during  hospitalization  has  been  shown
to  result  in  better  outcomes,  such  as  improved  glycaemic
control  [117], fewer  readmissions  for  diabetes  [117,118],
reduced  length  of  hospital  stays  [118]  and  reduced  costs
[118].  In  diabetic  patients  hospitalized  for  conditions  other
than  diabetes,  referral  to  an  endocrinologist/diabetologist
has  been  shown  to  signiﬁcantly  reduce  the  mean  hospital
length  of  stay  from  8.2  to  5.5  days  [119].
CONSENSUS  STATEMENT  (REFERRAL  TO  A
DIABETOLOGIST)
1.  In  the  cardiology  ICU,  the  treatment  of  diabetes  or
stress  hyperglycaemia  that  requires  insulin  needs  to
be  delivered  by  an  experienced  team  that  includes
a  diabetologist  (professional  agreement).
2.  Referral  to  a  diabetologist  before  hospital
discharge:  the  patient  should  be  referred  to  a
diabetologist  before  discharge  from  hospital  in
the  following  situation:
•  unknown  diabetes,  diagnosed  during  ACS
hospitalization  (HbA1c ≥  6.5%);
•  and/or  known  diabetes  with  admission  HbA1c
greater  or  equal  to  8%;
•  and/or  newly  introduced  insulin  therapy;
•  and/or  severe/repeated  hypoglycaemia  (Level  B).
If  a  diabetologist  is  not  available,  the  cardiologist
should  contact  a  diabetology  department  to  organize
hospitalization  following  hospitalization  in  the
cardiology  department  (professional  agreement).
3. Referral  to  a  diabetologist  after  hospital
discharge:
• In  patients  without  diabetes  at  discharge  (no
known  diabetes  at  admission  and  admission
HbA1c <  6.5%),  it  is  recommended  to  perform  an
OGTT  between  days  7  and  28.  If  diabetes  is
diagnosed  by  the  OGTT,  the  patient  should  be
referred  to  a  diabetologist  for  education,  initiation
of  antidiabetic  therapy  and  planning  of  the  future
follow-up  of  the  patient  in  coordination  with  the
primary-care  physician  (professional  agreement).
•  Follow-up  of  the  patient  with  diabetes  should
be  coordinated  with  the  primary-care  physician
(professional  agreement).
•  After  discharge,  the  patients  with  diabetes  may
be  referred  to  centres  specializing  in  diabetes
education  if  available  (professional  agreement).
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ddendum.
roposed  insulin  protocol  for  cardiology  intensive  care  unit:
Use  rapid-acting  insulin  analogs  (50  units  diluted  in  50  ml
Glucose  5%).
A  parallel  infusion  of  Glucose  5%  is  also  set  up.
A  total  amount  of  150  g  of  carbohydrates  a  day  has  to  be
given  (including  both  Glucose  5%  infusion  and  oral  food).
nitial  dose:  the  initial  dose  of  insulin  depends  on  the  admis-
ion  blood  glucose  (BG).
dmission  BG Insulin  dose
80—300  mg/dL  (10—16.6  mmol/L)  2  U/h
00—400  mg/dL  (16.6—22.2  mmol/L)  3  U/h
 400  mg/dL  (22.2  mmol/L)  4  U/h
hen,  insulin  dosage  will  be  adapted  to  BG  level  (monitored
 hr  after  initiation,  then  every  2  hours).
G  level  Insulin  dose
 80  mg/dL  (4.4  mmol/L) Stop  insulin
0—140  mg/dL  (4.4—7.8  mmol/L)  by  0.5  U/h
40—180  mg/dL  (7.8—10  mmol/L)  unchanged
80—300  mg/dL  (10—16.6  mmol/L)  by  1  U/h
 300  mg/dL  (16.6  mmol/L)  by  1.5  U/h
n  patients  older  than  75  years  old,  insulin  dosage  could  be
dapted  to  BG  as  follows.
G  level  Insulin  dose
 80  mg/dL  (4.4  mmol/L)  Stop  insulin
0—140  mg/dL  (4.4—7.8  mmol/L)  Stop  insulin
40—180  mg/dL  (7.8—10  mmol/L)  unchanged
80—300  mg/dL  (10—16.6  mmol/L)  by  0.5  U/h
 300  mg/dL  (16.6  mmol/L) by  1  U/h
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If the  patient  eats,  a  bolus  of  insulin  will  be  given  with
an  initial  bolus  dose  of  4  units.  Thereafter,  the  bolus  dose
will  be  adapted  according  to  the  postprandial  BG  levels.
In  cases  of  mild  hypoglycaemia  (BG  <  80  mg/dL
[4.4  mmol/L]),  insulin  infusion  is  stopped  and  15  g
oral  sugar  is  given  to  the  patient.  BG  testing  is  performed
every  30  minutes  and  insulin  infusion  is  re-started  when
BG  >  140  mg/dL  (7.8  mmol/L)  with  half  of  the  previous
insulin  infusion  rate.
In  cases  of  severe  hypoglycaemia  (BG  <  40  mg/dL
[2.2  mmol/L]),  Glucose  30%  is  injected  into  the  patient.
Proposed  protocol  for  transition  from  intravenous  to  sub-
utaneous  insulin  [120]:
. Calculate  the  average  insulin  intravenous  infusion  rate
in  the  last  12  hours  to  obtain  the  mean  hourly  rate  and
multiply  by  24  to  get  the  total  daily  insulin  requirement.
.  Halve  this  24-h  insulin  dose  to  obtain  the  long-acting
insulin  analog  dose  and  total  daily  rapid-acting  insulin
analog  dose.
.  Give  the  long-acting  insulin  analog  subcutaneous  mono-
dose  2  hours  before  the  ﬁrst  meal  and  the  discontinuation
of  intravenous  glucose  infusion.
.  Split  the  total  daily  rapid-acting  insulin  analog  dose  into
20%  at  breakfast,  40%  at  lunch  and  40%  at  dinner,  accord-
ing  to  a  similar  distribution  of  carbohydrates  in  the
typical  Mediterranean  diet.
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